DOCSLIB.ORG

25% OFF Full-Size Primary Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
25% OFF Full-Size Primary Antibody GeneTex Antibodies with Citations - 25% OFF full-size Primary Antibody List of Eligible Products Cat No. Product Name GTX130274 CD31 antibody GTX127309 HIF1 alpha antibody GTX635679 SARS-CoV-2 (COVID-19) nucleocapsid antibody [HL344] GTX632604 SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] GTX42110 CD3 epsilon antibody [CD3-12] GTX31878 SLC27A6 antibody GTX101125 LPL antibody GTX100118 GAPDH antibody GTX118000 STAT3 (phospho Tyr705) antibody GTX53048 ULBP2 antibody [7F33] GTX130422 IRF3 (phospho Ser386) antibody GTX121677 Histone H3K9me3 (Tri-methyl Lys9) antibody GTX101452 DYNC1H1 antibody GTX86952 Caspase 3 (cleaved Asp175) antibody GTX85378 CUEDC1 antibody GTX84785 BTK antibody [10E10] GTX84377 HDAC6 antibody [4C5] GTX77457 DDDDK tag antibody GTX76185 CD9 antibody [MM2/57] GTX76060 CD11b antibody [OX-42] GTX74034 IL1 beta antibody GTX70485 Ku80 antibody GTX70268 Hec1 antibody [9G3.23] GTX632426 Iba1 antibody [GT10312] GTX629630 beta Actin antibody [GT5512] GTX629117 Dengue virus Envelope protein antibody [GT643] GTX628802 alpha Tubulin antibody [GT114] GTX627408 GAPDH antibody [GT239] GTX60661 ABCB5 antibody [5H3C6] GTX59618 ERK1/2 antibody GTX55142 COL11A1 antibody GTX54648 Cruciform DNA antibody [2D3] GTX54088 HMGCR antibody GTX54007 FBP1 antibody GTX51959 SRX1 antibody GTX50128 AKT (phospho Ser473) antibody GTX50090 GSK3 beta (phospho Ser9) antibody GTX41877 CD63 antibody [AD1] GTX41794 CD81 antibody [Eat2] GTX41286 Collagen I antibody GTX39744 Marco antibody [ED31] GTX32224 IKB alpha (phospho Ser32/Ser36) antibody GTX31308 PD-L1 antibody GTX30773 NeuN antibody [2Q158] GTX30448 DOPA Decarboxylase antibody GTX26640 F4/80 antibody [CI:A3-1] GTX26276 beta Actin antibody [AC-15] GTX24822 p38 MAPK (phospho Thr180/Tyr182) antibody GTX24819 ERK1 (phospho Thr202/Tyr204) + ERK2 (phospho Thr185/Tyr187) antibody GTX23364 P Glycoprotein antibody [C219] GTX21279 TGF beta antibody [TB21] GTX16667 Ki67 antibody [SP6] GTX14321 F4/80 antibody [CI:A3-1] GTX134052 Doublecortin antibody GTX133475 SMAD2 (phospho Ser245/Ser250/Ser255) antibody GTX133317 Zika virus Capsid protein antibody GTX133314 Zika virus Envelope protein antibody GTX133311 Zika virus NS4B protein antibody GTX133309 Zika virus NS3 protein antibody GTX132346 Coxsackievirus A6 VP1 antibody GTX132329 PARP (cleaved Asp214) antibody GTX132298 Caspase 12 antibody GTX132244 Cxcr4b antibody GTX132081 Acetyl-CoA Carboxylase 1 antibody GTX131961 West Nile virus NS5 protein antibody GTX131955 West Nile virus NS3 protein antibody GTX131406 Leptin b antibody GTX129846 c-Fos antibody GTX129841 SMAD3 (phospho Ser423/425) antibody GTX129186 LEF1 antibody GTX128752 Cdx4 antibody GTX128414 AKT (phospho Ser473) antibody GTX128374 Sox10 antibody GTX125990 Influenza A virus NS1 (nonstructural protein) antibody GTX125989 Influenza A virus NP (nucleoprotein) antibody GTX125974 Influenza A virus H1N1 NA (Neuraminidase) antibody GTX125928 Influenza A virus M1 (matrix protein) antibody GTX125926 Influenza A virus PB2 protein antibody GTX125923 Influenza A virus PB1 protein antibody GTX125888 TET1 antibody [N1], N-term GTX125851 Renilla Luciferase antibody GTX124496 Pcna antibody GTX124346 Cbsa antibody GTX124250 Dengue virus NS4B protein antibody GTX123973 ALDH1A1 antibody GTX121937 AKT antibody [N3C2], Internal GTX120929 NKAP antibody GTX120402 DSN1 antibody [N3C3] GTX120134 ZC3HAV1 antibody [N3C2], Internal GTX118991 Influenza A virus PA protein antibody GTX116093 SOD2 antibody GTX116040 GPX1 antibody GTX116036 FABP4 antibody [N3C3] GTX114918 SF2 antibody GTX114399 FACL4 antibody [N1N3] GTX114337 CPT1A antibody [C1C2], Internal GTX113839 SNAP25 antibody GTX113617 GFP antibody GTX113340 Grp78 antibody GTX112799 alpha Synuclein antibody GTX112794 Fibronectin antibody [N1N2], N-term GTX111643 Collagen III antibody [C2C3-2], C-term GTX111192 GSK3 beta antibody [C1C3] GTX111088 Hsp70 antibody GTX110562 ERCC1 antibody [N1C3] GTX110536 CSRP3 antibody GTX110089 HSP60 antibody GTX109941 ATGL antibody [N1C1] GTX109833 Fatty Acid Synthase antibody [N1], N-term GTX109766 DLAT antibody GTX109753 Hsp90 alpha antibody GTX109639 beta Actin antibody GTX108711 GFAP antibody GTX108524 RAMP2 antibody GTX107538 MLKL antibody GTX106464 UBE2T antibody [C2C3], C-term GTX106148 Hsp70 antibody GTX105792 Glyoxalase I antibody [N1C3] GTX104763 PD-L1 antibody GTX104590 RCC1 antibody GTX104255 GOLGA5 antibody [N2C2], Internal GTX104122 ME1 antibody GTX103322 NRF2 antibody [N2C2], Internal GTX102595 53BP1 antibody [N1], N-term GTX101943 ATF4 antibody GTX101767 Calmodulin antibody GTX101705 PRX I antibody [N1C2] GTX101507 SOX2 antibody [N1C3] GTX101147 Heme Oxygenase 1 antibody GTX100863 Nanog antibody [N3C3] GTX100685 SQSTM1 / P62 antibody [N3C1], Internal GTX100659 SOD1 antibody GTX100642 CD36 antibody [C1C3] GTX100619 Vimentin antibody GTX100554 SOD1 antibody GTX100469 Rad51 antibody [N1C2] GTX100450 ICAM1 / CD54 antibody [N1C2] GTX100443 E-Cadherin antibody GTX100065 Chk1 (phospho Ser345) antibody [C1C2], Internal GTX100064 Bcl-2 antibody [N1N2], N-term GTX100055 APXL antibody [C3], C-term GTX100052 Survivin antibody GTX100042 Iba1 antibody GTX100034 alpha Smooth Muscle Actin antibody GTX01754 Mucin 4 antibody [8G7] GTX60577 CYP3A4 antibody [3H8] GTX129593 AMH antibody GTX130246 iNOS antibody GTX49179 KAP1 antibody [4E1-D12-F8] GTX21276 SMC1 (phospho Ser966) antibody GTX82813 SMC1 antibody [5B6] GTX629631 DDDDK tag antibody [GT231] GTX107692 SCRIB antibody GTX132339 Enterovirus 71 VP1 antibody GTX75843 Granzyme B antibody [GB11] GTX627408-01 GAPDH antibody [GT239] (HRP) GTX70230 Rad51 antibody [14B4] GTX629116 Dengue virus Envelope protein antibody [GT214] GTX72989 Placental Alkaline Phosphatase antibody GTX83567 Serine racemase antibody [9E8] GTX70224 NBS1 antibody [1D7] GTX82570 Tyrosine Hydroxylase antibody GTX30114 HIF2 alpha antibody GTX129840 FAK (phospho Tyr397) antibody GTX134209 TGF beta Receptor I antibody GTX630148 Ubiquitin antibody [GT7811] GTX22404 Myelin basic protein antibody GTX83792 PROM2 antibody [14D1] GTX134234 MEK1 antibody GTX55814 TGF beta Receptor 2 antibody GTX127345 N-Cadherin antibody GTX01102 PDGF Receptor alpha antibody [JF104-6] GTX01495 PD-L1 antibody [29E.2A3] GTX129909 TGF beta Receptor 2 antibody GTX130023 TGF beta 1 antibody GTX20254 SENP1 antibody GTX109331 Cardiac Troponin I antibody [N1C3] GTX102326 EEF1A2 antibody GTX112784 UCP1 antibody GTX105608 FKBP25 antibody [N1C3] GTX82968 Tn antigen antibody [Tn 218] GTX100928 Angiopoietin 2 antibody GTX124252 Dengue virus NS3 protein antibody GTX103343 Dengue virus Capsid protein antibody GTX132982 VE-Cadherin antibody GTX128538 Influenza B virus Nucleoprotein antibody GTX84173 LTA4H antibody [6B5] GTX85454 GFAP antibody GTX109242 Arginase 1 antibody GTX00976 IKB alpha (phospho Ser32) antibody [ST53-05] GTX110521 IKB alpha antibody GTX35098 Tenascin C antibody [SPM319] GTX111525 Hexokinase II antibody GTX77365 beta Galactosidase antibody GTX102170 FOXM1 antibody GTX125868 Japanese encephalitis Virus NS3 antibody GTX106323 KPNA2 antibody [C3], C-term GTX22811 Importin beta 1 antibody [3E9] GTX76407 Integrin alpha 4 antibody [HP2/1] GTX121928 Nesprin 2 antibody [C3], C-term GTX109637 PGP9.5 antibody GTX110543 Caspase 3 antibody GTX628901 COX4 antibody [GT854] GTX55251 p107 antibody GTX116080 LC3B antibody [N1C3] GTX105620 AKR1C1 antibody GTX135119 CDKN2A / p16INK4a antibody GTX87122 OR2W3 antibody GTX100665 MMP13 antibody [N3C1], Internal GTX54920 Aggrecan antibody GTX36254 CaMKII (oxidized) antibody GTX30518 c-Myc antibody GTX59712 Cathepsin K antibody GTX116510 SMYD2 antibody GTX70212 Mre11 antibody [12D7] GTX107737 FOXP3 antibody [C3], C-term GTX632062 DCK antibody [GT7710] GTX631836 beta Tubulin 3/ Tuj1 antibody [GT11710] GTX112846 CREB antibody GTX130379 CREB (phospho Ser133) antibody GTX128146 ATR antibody GTX127905 HYPB/SETD2 antibody GTX89577 SNAP25 antibody, C-term GTX128127 Pax2a antibody GTX111453 DDR1 antibody [N1N3] GTX11512 E-Cadherin antibody [DECMA-1] GTX104618 Triosephosphate isomerase antibody [C2C3], C-term GTX108585 Cytochrome C antibody GTX56293 CYP11A1 antibody GTX110520 TNF alpha antibody GTX124213 beta Actin antibody GTX14515 COMP antibody GTX111071 RSK3 antibody [N2C1], Internal GTX79258 JunB antibody GTX11843 E2F3 antibody [PG30] GTX105495 AChR alpha 3 antibody GTX115378 NDP52 antibody GTX89701 alpha Smooth Muscle Actin antibody, N-term GTX100332 ADAMTS5 antibody GTX107897 Casein Kinase 2 alpha antibody GTX32465 Bax antibody GTX109255 ANP antibody GTX16198 TNF Receptor I antibody [HM104] (PE) GTX89570 Renalase (aa 224 to 233) antibody, Internal GTX128093 Dengue virus prM protein antibody GTX629477 Dengue virus NS3 protein antibody [GT2811] GTX127277 Dengue virus Envelope protein antibody GTX19247 Ubiquitin antibody GTX111401 CaMKII delta antibody GTX108105 Munc 13-4 antibody [C3], C-term GTX128796 SLUG antibody GTX128508 mCherry antibody GTX82524 EIF4E2 antibody GTX102643 VEGF antibody GTX129151 YAP1 antibody GTX48691 Jagged 1 antibody GTX109749 Vinculin antibody [N3C1], Internal GTX101676 Calnexin antibody [N3C2], Internal GTX50002 KCTD15 antibody [AT4C3] GTX127342 Histone H2A.XS139ph (phospho Ser139) antibody GTX104616 STAT3 antibody [C3], C-term GTX627419 Oct4 antibody [GT486] GTX627421 Nanog antibody [GT3312] GTX127310 Twist1/2 antibody GTX117120 CYP3A43 antibody GTX55429 NCF1 (phospho Ser359) antibody GTX59788 mCherry antibody GTX103977 EIF4E2 antibody [N1C3] GTX118619 RBPMS antibody GTX77436 V5 tag antibody (Biotin) GTX111168 alpha Catenin antibody [N1N3] GTX110564 beta Actin antibody GTX133307 Zika
Load more

Recommended publications
  • MDR-1, Bcl-Xl, H. Pylori, and Wnt&Sol;Β-Catenin Signalling in the Adult Stomach
    Laboratory Investigation (2012) 92, 1670–1673 & 2012 USCAP, Inc All rights reserved 0023-6837/12 $32.00 EDITORIAL MDR-1, Bcl-xL, H. pylori, and Wnt/b-catenin signalling in the adult stomach: how much is too much? R John MacLeod Laboratory Investigation (2012) 92, 1670–1673; doi:10.1038/labinvest.2012.151 ultiple drug resistance (MDR) is a interaction between the antiapoptotic protein major cause of failure of che- Bcl-xL and MDR-1. Knockdown of MDR-1 motherapy in cancer treatment. increases the apoptotic index of these cells exposed The membrane transporter P-gly- to oxidative stress consistent with a role for MDR- coprotein (MDR-1, Pgp) encoded 1 in apoptosis. Several questions emerge from Mby the adenosine triphosphate-binding cassette, these findings. The first is why is MDR-1 increased subfamily B, member 1 is the main mechanism for in some HP-positive mucosa but in 100% of the decreased intracellular drug accumulation in MDR intestinal metaplasia samples? A likely causative cancer.1 Increases in Mdr-1 expression prevent effector of the increase in MDR-1 is the activation tumor cells from a variety of induced apoptosis, of canonical or Wnt/b-catenin signaling. It has but how this occurs is poorly understood. It is been known for a dozen years that the MDR-1 essential to understand how this occurs to be able gene may be stimulated by Tcf4.4 Yamada et al4 to design effective therapeutic interventions. The clearly demonstrated the presence of Tcf4 sites on study by Rocco et al2 (this issue) clearly shows that the MDR-1 promoter and showed that MDR-1 in the mitochondria of gastric cancer cell lines protein had substantially increased in adenomas MDR1 physically interacts with Bcl-xL, a well- and colon cancer.
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • In Vivo Imaging of Tgfβ Signalling Components Using Positron
    REVIEWS Drug Discovery Today Volume 24, Number 12 December 2019 Reviews KEYNOTE REVIEW In vivo imaging of TGFb signalling components using positron emission tomography 1 1 2 Lonneke Rotteveel Lonneke Rotteveel , Alex J. Poot , Harm Jan Bogaard , received her MSc in drug 3 1 discovery and safety at the Peter ten Dijke , Adriaan A. Lammertsma and VU University in 1 Amsterdam. She is Albert D. Windhorst currently finishing her PhD at the VU University 1 Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands Medical Center (VUmc) 2 under the supervision of A. Pulmonary Medicine, Institute for Cardiovascular Research, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands D. Windhorst and Adriaan A. Lammertsma. Her 3 research interest is on the development of positron Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center, Leiden, The emission tomography (PET) tracers that target Netherlands selectively the activin receptor-like kinase 5 in vitro and in vivo. Alex J. Poot obtained his The transforming growth factor b (TGFb) family of cytokines achieves PhD in medicinal chemistry homeostasis through a careful balance and crosstalk with complex from Utrecht University. As postdoctoral researcher at signalling pathways. Inappropriate activation or inhibition of this pathway the VUmc, Amsterdam, he and mutations in its components are related to diseases such as cancer, developed radiolabelled anticancer drugs for PET vascular diseases, and developmental disorders. Quantitative imaging of imaging. In 2014, he accepted a research expression levels of key regulators within this pathway using positron fellowship from Memorial Sloan Kettering Cancer 13 emission tomography (PET) can provide insights into the role of this Center, New York to develop C-labelled probes for tumour metabolism imaging with magnetic resonance in vivo pathway , providing information on underlying pathophysiological imaging (MRI).
    [Show full text]
  • Targeting the Tryptophan Hydroxylase 2 Gene for Functional Analysis in Mice and Serotonergic Differentiation of Embryonic Stem Cells
    TARGETING THE TRYPTOPHAN HYDROXYLASE 2 GENE FOR FUNCTIONAL ANALYSIS IN MICE AND SEROTONERGIC DIFFERENTIATION OF EMBRYONIC STEM CELLS Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Dana Kikic, M.Sc. in Molecular biology and Physiology from Nis June, 2009 The doctorate studies were performed in the research group of Prof. Michael Bader Molecular Biology of Peptide Hormones at Max-Delbrück-Center for Molecular Medicine in Berlin, Buch Mai 2005 - September 2008. 1st Reviewer: Prof. Michael Bader 2nd Reviewer: Prof. Udo Heinemann date of defence: 13. August 2009 ACKNOWLEDGMENTS Herewith, I would like to acknowledge the persons who made this thesis possible and without whom my initiation in the world of basic science research would not have the spin it has now, neither would my scientific illiteracy get the chance to eradicate. I am expressing my very personal gratitude and recognition to: Prof. Michael Bader, for an inexhaustible guidance in all the matters arising during the course of scientific work, for an instinct in defining and following the intellectual challenge and for letting me following my own, for necessary financial support, for defining the borders of reasonable and unreasonable, for an invaluable time and patience, and an amazing efficiency in supporting, motivating, reading, correcting and shaping my scientific language during the last four years. Prof. Harald Saumweber and Prof. Udo Heinemann, for taking over the academic supervision of the thesis, and for breathing in it a life outside the laboratory walls and their personal signature.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Human TGF Beta Receptor 2 ELISA Kit (ARG81882)
    Product datasheet [email protected] ARG81882 Package: 96 wells Human TGF beta Receptor 2 ELISA Kit Store at: 4°C Component Cat. No. Component Name Package Temp ARG81882-001 Antibody-coated 8 X 12 strips 4°C. Unused strips microplate should be sealed tightly in the air-tight pouch. ARG81882-002 Standard 2 X 10 ng/vial 4°C ARG81882-003 Standard/Sample 30 ml (Ready to use) 4°C diluent ARG81882-004 Antibody conjugate 1 vial (100 µl) 4°C concentrate (100X) ARG81882-005 Antibody diluent 12 ml (Ready to use) 4°C buffer ARG81882-006 HRP-Streptavidin 1 vial (100 µl) 4°C concentrate (100X) ARG81882-007 HRP-Streptavidin 12 ml (Ready to use) 4°C diluent buffer ARG81882-008 25X Wash buffer 20 ml 4°C ARG81882-009 TMB substrate 10 ml (Ready to use) 4°C (Protect from light) ARG81882-010 STOP solution 10 ml (Ready to use) 4°C ARG81882-011 Plate sealer 4 strips Room temperature Summary Product Description ARG81882 Human TGF beta Receptor 2 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human TGF beta Receptor 2 in serum, plasma (heparin, EDTA) and cell culture supernatants. Tested Reactivity Hu Tested Application ELISA Specificity There is no detectable cross-reactivity with other relevant proteins. Target Name TGF beta Receptor 2 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 7.8 pg/ml Sample Type Serum, plasma (heparin, EDTA) and cell culture supernatants. Standard Range 15.6 - 1000 pg/ml Sample Volume 100 µl www.arigobio.com 1/3 Precision Intra-Assay CV: 5.3%; Inter-Assay CV: 6.0% Alternate Names FAA3; AAT3; TbetaR-II; TGF-beta receptor type-2; LDS2B; MFS2; TGF-beta type II receptor; EC 2.7.11.30; TAAD2; TGFR-2; LDS2; Transforming growth factor-beta receptor type II; TGFbeta-RII; TGF-beta receptor type II; RIIC; LDS1B Application Instructions Assay Time ~ 5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C.
    [Show full text]
  • A Cytokine Protein-Protein Interaction Network for Identifying Key Molecules in Rheumatoid Arthritis
    RESEARCH ARTICLE A cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis Venugopal Panga1,2, Srivatsan Raghunathan1* 1 Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronics City Phase I, Bengaluru, Karnataka, India, 2 Manipal Academy of Higher Education, Manipal, Karnataka, India * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovial joints. Though the current RA therapeutics such as disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics can halt the progression of the disease, none of these would either dramatically reduce or cure RA. So, the identification of OPEN ACCESS potential therapeutic targets and new therapies for RA are active areas of research. Several Citation: Panga V, Raghunathan S (2018) A studies have discovered the involvement of cytokines in the pathogenesis of this disease. cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis. These cytokines induce signal transduction pathways in RA synovial fibroblasts (RASF). PLoS ONE 13(6): e0199530. https://doi.org/ These pathways share many signal transducers and their interacting proteins, resulting in 10.1371/journal.pone.0199530 the formation of a signaling network. In order to understand the involvement of this network Editor: Hua Zhou, Macau University of Science and in RA pathogenesis, it is essential to identify the key transducers and their interacting pro- Technology, MACAO teins that are part of this network. In this study, based on a detailed literature survey, we Received: August 21, 2017 have identified a list of 12 cytokines that induce signal transduction pathways in RASF.
    [Show full text]
  • Table 1A SIRT1 Differential Binding Gene List Down
    Rp1 Rb1cc1 Pcmtd1 Mybl1 Sgk3 Cspp1 Arfgef1 Cpa6 Kcnb2 Stau2 Jph1 Paqr8 Kcnq5 Rims1 Smap1 Bai3 Prim2 Bag2 Zfp451 Dst Uggt1 4632411B12Rik Fam178b Tmem131 Inpp4a 2010300C02Rik Rev1 Aff3 Map4k4 Il1r1 Il1rl2 Tgfbrap1 Col3a1 Wdr75 Tmeff2 Hecw2 Boll Plcl1 Satb2 Aox4 Mpp4 Gm973 Carf Nbeal1 Pard3b Ino80d Adam23 Dytn Pikfyve Atic Fn1 Smarcal1 Tns1 Arpc2 Pnkd Ctdsp1 Usp37 Acsl3 Cul3 Dock10 Col4a4 Col4a3 Mff Wdr69 Pid1 Sp110 Sp140 Itm2c 2810459M11Rik Dis3l2 Chrng Gigyf2 Ugt1a7c Ugt1a6b Hjurp A730008H23Rik Trpm8 Kif1a D1Ertd622e Pam Cntnap5b Rnf152 Phlpp1 Clasp1 Gli2 Dpp10 Tmem163 Zranb3 Pfkfb2 Pigr Rbbp5 Sox13 Ppfia4 Rabif Kdm5b Ppp1r12b Lgr6 Pkp1 Kif21b Nr5a2 Dennd1b Trove2 Pdc Hmcn1 Ncf2 Nmnat2 Lamc2 Cacna1e Xpr1 Tdrd5 Fam20b Ralgps2 Sec16b Astn1 Pappa2 Tnr Klhl20 Dnm3 Bat2l2 4921528O07Rik Scyl3 Dpt Mpzl1 Creg1 Cd247 Gm4846 Lmx1a Pbx1 Ddr2 Cd244 Cadm3 Fmn2 Grem2 Rgs7 Fh1 Wdr64 Pld5 Cep170 Akt3 Pppde1 Smyd3 Parp1 Enah Capn8 Susd4 Mosc1 Rrp15 Gpatch2 Esrrg Ptpn14 Smyd2 Tmem206 Nek2 Traf5 Hhat Cdnf Fam107b Camk1d Cugbp2 Gata3 Itih5 Sfmbt2 Itga8 Pter Rsu1 Ptpla Slc39a12 Cacnb2 Nebl Pip4k2a Abi1 Tbpl2 Pnpla7 Kcnt1 Camsap1 Nacc2 Gpsm1 Sec16a Fam163b Vav2 Olfm1 Tsc1 Med27 Rapgef1 Pkn3 Zer1 Prrx2 Gpr107 Ass1 Nup214 Bat2l Dnm1 Ralgps1 Fam125b Mapkap1 Hc Ttll11 Dennd1a Olfml2a Scai Arhgap15 Gtdc1 Mbd5 Kif5c Lypd6b Lypd6 Fmnl2 Arl6ip6 Galnt13 Acvr1 Ccdc148 Dapl1 Tanc1 Ly75 Gcg Kcnh7 Cobll1 Scn3a Scn9a Scn7a Gm1322 Stk39 Abcb11 Slc25a12 Metapl1 Pdk1 Rapgef4 B230120H23Rik Gpr155 Wipf1 Pde11a Prkra Gm14461 Pde1a Calcrl Olfr1033 Mybpc3 F2 Arhgap1 Ambra1 Dgkz Creb3l1
    [Show full text]
  • Pituitary Stem Cells Produce Paracrine WNT Signals to Control The
    RESEARCH ARTICLE Pituitary stem cells produce paracrine WNT signals to control the expansion of their descendant progenitor cells John P Russell1, Xinhong Lim2,3, Alice Santambrogio1,4, Val Yianni1, Yasmine Kemkem5, Bruce Wang6,7, Matthew Fish6, Scott Haston8, Anae¨ lle Grabek9, Shirleen Hallang1, Emily J Lodge1, Amanda L Patist1, Andreas Schedl9, Patrice Mollard5, Roel Nusse6, Cynthia L Andoniadou1,4* 1Centre for Craniofacial and Regenerative Biology, King’s College London, London, United Kingdom; 2Skin Research Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore; 3Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; 4Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universita¨ t Dresden, Dresden, Germany; 5Institute of Functional Genomics (IGF), University of Montpellier, CNRS, Montpellier, France; 6Howard Hughes Medical Institute, Stanford University School of Medicine, Department of Developmental Biology, Stanford University School of Medicine, Stanford, United States; 7Department of Medicine and Liver Center, University of California San Francisco, San Francisco, United States; 8Developmental Biology and Cancer, Birth Defects Research Centre, UCL GOS Institute of Child Health, London, United Kingdom; 9Universite´ Coˆte d’Azur, Inserm, CNRS, Nice, France Abstract In response to physiological demand, the pituitary gland generates new hormone- secreting cells from committed progenitor cells throughout life. It remains unclear to what extent pituitary stem cells (PSCs), which uniquely express SOX2, contribute to pituitary growth and renewal. Moreover, neither the signals that drive proliferation nor their sources have been *For correspondence: elucidated. We have used genetic approaches in the mouse, showing that the WNT pathway is [email protected] essential for proliferation of all lineages in the gland.
    [Show full text]
  • (51) International Patent Classification: C12N 5/0783 (2010.01) A61K 35/1 7 (2015.01) Declarations Under Rule 4.17: C12N 5/10 (2
    ( (51) International Patent Classification: Declarations under Rule 4.17: C12N 5/0783 (2010.01) A61K 35/1 7 (2015.01) — as to applicant's entitlement to apply for and be granted a C12N 5/10 (2006.01) A61P 35/00 (2006.01) patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/US2020/0 18443 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 14 February 2020 (14.02.2020) — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (25) Filing Language: English claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) (30) Priority Data: 62/806,457 15 February 2019 (15.02.2019) US 62/841,066 30 April 2019 (30.04.2019) US 62/841,684 0 1 May 2019 (01.05.2019) US 62/943,649 04 December 2019 (04. 12.2019) US (71) Applicant: EDITAS MEDICINE, INC. [US/US] ; 11Hur¬ ley Street, Cambridge, MA 02141 (US). (72) Inventors: WELSTEAD, Gordon, Grant; 12 Devon Ter¬ race, Newton, MA 02459 (US). BORGES, Christopher; 2 1 Cumberland Rd Reading, MA 01867 (US). WONG, Karrie, Kawai; 20 Warwick Street, Unit 3, Somerville, MA 02145 (US). (74) Agent: ZACHARAKIS, Maria, Laccotripe et a ; Mc¬ Carter & English, LLP, 265 Franklin Street, Boston, MA 021 10 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
    [Show full text]
  • An Evolutionary Based Strategy for Predicting Rational Mutations in G Protein-Coupled Receptors
    Ecology and Evolutionary Biology 2021; 6(3): 53-77 http://www.sciencepublishinggroup.com/j/eeb doi: 10.11648/j.eeb.20210603.11 ISSN: 2575-3789 (Print); ISSN: 2575-3762 (Online) An Evolutionary Based Strategy for Predicting Rational Mutations in G Protein-Coupled Receptors Miguel Angel Fuertes*, Carlos Alonso Department of Microbiology, Centre for Molecular Biology “Severo Ochoa”, Spanish National Research Council and Autonomous University, Madrid, Spain Email address: *Corresponding author To cite this article: Miguel Angel Fuertes, Carlos Alonso. An Evolutionary Based Strategy for Predicting Rational Mutations in G Protein-Coupled Receptors. Ecology and Evolutionary Biology. Vol. 6, No. 3, 2021, pp. 53-77. doi: 10.11648/j.eeb.20210603.11 Received: April 24, 2021; Accepted: May 11, 2021; Published: July 13, 2021 Abstract: Capturing conserved patterns in genes and proteins is important for inferring phenotype prediction and evolutionary analysis. The study is focused on the conserved patterns of the G protein-coupled receptors, an important superfamily of receptors. Olfactory receptors represent more than 2% of our genome and constitute the largest family of G protein-coupled receptors, a key class of drug targets. As no crystallographic structures are available, mechanistic studies rely on the use of molecular dynamic modelling combined with site-directed mutagenesis data. In this paper, we hypothesized that human-mouse orthologs coding for G protein-coupled receptors maintain, at speciation events, shared compositional structures independent, to some extent, of their percent identity as reveals a method based in the categorization of nucleotide triplets by their gross composition. The data support the consistency of the hypothesis, showing in ortholog G protein-coupled receptors the presence of emergent shared compositional structures preserved at speciation events.
    [Show full text]
  • Onset of Taste Bud Cell Renewal Starts at Birth and Coincides with a Shift In
    RESEARCH ARTICLE Onset of taste bud cell renewal starts at birth and coincides with a shift in SHH function Erin J Golden1,2, Eric D Larson2,3, Lauren A Shechtman1,2, G Devon Trahan4, Dany Gaillard1,2, Timothy J Fellin1,2, Jennifer K Scott1,2, Kenneth L Jones4, Linda A Barlow1,2* 1Department of Cell & Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, United States; 2The Rocky Mountain Taste and Smell Center, University of Colorado Anschutz Medical Campus, Aurora, United States; 3Department of Otolaryngology, University of Colorado Anschutz Medical Campus, Aurora, United States; 4Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant, University of Colorado Anschutz Medical Campus, Aurora, United States Abstract Embryonic taste bud primordia are specified as taste placodes on the tongue surface and differentiate into the first taste receptor cells (TRCs) at birth. Throughout adult life, TRCs are continually regenerated from epithelial progenitors. Sonic hedgehog (SHH) signaling regulates TRC development and renewal, repressing taste fate embryonically, but promoting TRC differentiation in adults. Here, using mouse models, we show TRC renewal initiates at birth and coincides with onset of SHHs pro-taste function. Using transcriptional profiling to explore molecular regulators of renewal, we identified Foxa1 and Foxa2 as potential SHH target genes in lingual progenitors at birth and show that SHH overexpression in vivo alters FoxA1 and FoxA2 expression relevant to taste buds. We further bioinformatically identify genes relevant to cell adhesion and cell *For correspondence: locomotion likely regulated by FOXA1;FOXA2 and show that expression of these candidates is also LINDA.BARLOW@CUANSCHUTZ. altered by forced SHH expression.
    [Show full text]